Strs Ohio held its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the second quarter, Holdings Channel reports. The firm owned 55,993 shares of the company’s stock at the end of the second quarter. Strs Ohio’s holdings in Teva Pharmaceutical Industries Limited were worth $1,860,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Cribstone Capital Management LLC boosted its stake in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares in the last quarter. Bronfman E.L. Rothschild L.P. boosted its stake in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares in the last quarter. FNY Managed Accounts LLC bought a new stake in Teva Pharmaceutical Industries Limited during the first quarter worth approximately $123,000. Sterling Investment Advisors Ltd. boosted its stake in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares in the last quarter. Finally, Cutler Capital Management LLC bought a new stake in Teva Pharmaceutical Industries Limited during the second quarter worth approximately $133,000. Institutional investors and hedge funds own 56.27% of the company’s stock.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 17.19 on Friday. The firm’s market cap is $17.47 billion. Teva Pharmaceutical Industries Limited has a 12 month low of $17.12 and a 12 month high of $55.39. The firm’s 50-day moving average price is $30.08 and its 200-day moving average price is $31.67.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same period in the previous year, the company posted $1.25 earnings per share. The company’s quarterly revenue was up 12.9% on a year-over-year basis. Equities research analysts predict that Teva Pharmaceutical Industries Limited will post $4.39 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be issued a $0.085 dividend. The ex-dividend date is Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.98%. Teva Pharmaceutical Industries Limited’s payout ratio is presently -18.95%.

COPYRIGHT VIOLATION NOTICE: “Strs Ohio Has $1,860,000 Stake in Teva Pharmaceutical Industries Limited (TEVA)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/strs-ohio-has-1860000-stake-in-teva-pharmaceutical-industries-limited-teva/1472083.html.

A number of analysts recently commented on the company. Cantor Fitzgerald set a $31.00 price objective on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research report on Thursday, June 22nd. Vetr cut Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 price target for the company. in a report on Thursday, June 22nd. Zacks Investment Research cut Teva Pharmaceutical Industries Limited from a “hold” rating to a “strong sell” rating in a report on Wednesday. Credit Suisse Group restated an “outperform” rating and issued a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Finally, BidaskClub upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a report on Wednesday, July 5th. Three equities research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $37.69.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.